HIVE
HIVE Digital Technologies Ltd.
There isn't enough reported data to score HIVE yet.
JPM
JPMorgan Chase & Co.
JPM's fundamentals are strong, but it looks expensive: trading at 14x earnings, above its usual 12x. Analysts expect earnings growth.
HIVE Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| N/A | |
| N/A |
HIVE's revenue is currently healthy, but its profitability is weak. Free cash flow and net leverage aren't meaningful measures for financial services companies like HIVE.
JPM Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
JPM's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like JPM.
HIVE PE Valuation
HIVE has no meaningful PE right now: it lost money over the past year.
JPM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.7x | $231 | -33% |
| Fair | 12x | $287 | -16% |
| Current | 14x | $343 | — |
| Forward | 14x | $343 | — |
| Expensive | 15x | $361 | +5.2% |
Historical ranges are pointers, not guarantees.
JPM's PE is in its expensive range at 14.4x. If earnings grow as analysts expect, today's price would be 13.7x next year's earnings.
HIVE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect HIVE's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
JPM Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for JPM, with profitability improving.
HIVE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.60 | -1433% |
| Q2 2026 | -$1.38 | -1162% |
| Q1 2026 | -$0.66 | -$0.44 |
| Q4 2025 | -$0.27 | -154% |
| Q3 2025 | $0.12 | -71% |
| Q2 2025 | $0.13 | -28% |
| Q1 2025 | -$0.22 | -238% |
| Q4 2024 | $0.50 | +$0.98 |
HIVE has swung to a loss: it lost $1.60 per share over the past year, after a profit the year before.
JPM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $24.99 | +4.8% |
| Q3 2026 | $23.85 | +18% |
| Q2 2026 | $23.35 | +20% |
| Q1 2026 | $20.89 | +2.5% |
| Q4 2025 | $20.02 | +1.4% |
| Q3 2025 | $20.20 | +12% |
| Q2 2025 | $19.50 | +8.7% |
| Q1 2025 | $20.38 | +23% |
| Q4 2024 | $19.75 | +22% |
JPM has the edge over HIVE on earnings quality, reporting a profit while its opponent remains loss making.
HIVE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $84.9M | -2.7% |
| Q2 2026 | $79.1M | +73% |
| Q1 2026 | $71.8M | +130% |
| Q4 2025 | $93.1M | +219% |
| Q3 2025 | $87.3M | +285% |
| Q2 2025 | $45.6M | +41% |
| Q1 2025 | $31.2M | -16% |
| Q4 2024 | $29.2M | -6.5% |
HIVE's revenue is growing: $85M last quarter, down 2.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | -227% | -232 points |
| Q4 2025 | 18% | +25 points |
| Q3 2025 | -11% | +9.1 points |
| Q2 2025 | 78% | +132 points |
| Q1 2025 | 5.2% | -84 points |
| Q4 2024 | -7% | -30 points |
| Q3 2024 | -20% | -6.7 points |
| Q2 2024 | -54% | -68 points |
HIVE's operating margin was −227% last quarter, down 232 points from the same quarter a year ago, near the bottom of its range since 2019.
JPM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $50.2B | +8.1% |
| Q2 2026 | $57.3B | +28% |
| Q1 2026 | $49.8B | +10% |
| Q4 2025 | $45.8B | +7.1% |
| Q3 2025 | $46.4B | +8.8% |
| Q2 2025 | $44.9B | -11% |
| Q1 2025 | $45.3B | +8.1% |
| Q4 2024 | $42.8B | +11% |
JPM's revenue has grown year over year for five quarters in a row: $50.2B last quarter, up 8.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 40% | -0.2 points |
| Q2 2026 | 48% | +7.3 points |
| Q1 2026 | 41% | +0.5 points |
| Q4 2025 | 37% | -3.2 points |
| Q3 2025 | 40% | +0.6 points |
| Q2 2025 | 41% | -6 points |
| Q1 2025 | 41% | -0.6 points |
| Q4 2024 | 41% | +11 points |
JPM's operating margin was 40% last quarter, about level with the same quarter a year ago.
HIVE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $858K | +$49.1M |
| Q2 2026 | -$10.7M | +$26.4M |
| Q1 2026 | -$21.8M | +$7.8M |
| Q4 2025 | -$9M | +$80.9M |
| Q3 2025 | -$48.2M | -$26.2M |
| Q2 2025 | -$37.1M | -$19.4M |
| Q1 2025 | -$29.5M | +$8.3M |
| Q4 2024 | -$89.9M | -$63.8M |
HIVE has the edge over JPM on cash flow, with more consistent year-over-year improvement.
JPM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $33.2B | +$78.4B |
| Q2 2026 | -$25.3B | -186% |
| Q1 2026 | -$211.8B | +$40.1B |
| Q4 2025 | $119.7B | -19% |
| Q3 2025 | -$45.2B | +$28.9B |
| Q2 2025 | $29.5B | -23% |
| Q1 2025 | -$251.8B | -$97.7B |
| Q4 2024 | $147.8B | +145% |
JPM's free cash flow was −$84.2B over the past year, against −$120B the year before. Free cash flow isn't a meaningful measure for financial services companies like JPM.
HIVE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.9% | +7.8M shares |
| 1 year | +20% | +45.9M shares |
| 3 years | +222% | +189M shares |
| 5 years | +242% | +194M shares |
| Available history | +319% | +209M shares |
HIVE has 274M diluted shares, up 20% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
JPM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -11.2M shares |
| 1 year | -3.1% | -84.6M shares |
| 3 years | -8.5% | -249M shares |
| 5 years | -11% | -322M shares |
| Available history | -17% | -547M shares |
JPM has the edge over HIVE on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.1B |
| Q2 2026 | $6.8B |
| Q1 2026 | $8.3B |
| Q4 2025 | $8.3B |
| Q3 2025 | $8.3B |
| Q2 2025 | $7.5B |
| Q1 2025 | $7.5B |
| Q4 2024 | $4.3B |
JPM spent $24.5B buying back its own shares over the past year, down 11% from the year before.
HIVE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | 1.8x | Healthy |
| Q4 2025 | 0.0x | Very low |
| Q3 2025 | 0.0x | Very low |
| Q2 2025 | 0.3x | Very low |
| Q1 2025 | 4.1x | High |
| Q4 2024 | 0.2x | Very low |
| Q3 2024 | 0.3x | Very low |
| Q2 2024 | 0.0x | Very low |
HIVE's net debt is about 1.8 years of its operating earnings (EBITDA), down from 4.1 years a year ago. Net leverage isn't a meaningful measure for financial services companies like HIVE.
JPM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.5x | Very low |
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.6x | Very low |
| Q4 2025 | 0.5x | Very low |
| Q3 2025 | 0.6x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.4x | Very low |
JPM's net debt is less than a year of its operating earnings (EBITDA). Net leverage isn't a meaningful measure for financial services companies like JPM.
HIVE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.7 | Neutral |
| Stochastic | 6.1 | Oversold |
HIVE's weekly RSI is 35 (neutral) and its Stochastic is 6 (oversold).
JPM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.8 | Neutral |
| Stochastic | 31.5 | Neutral |
JPM's weekly RSI is 55 (neutral) and its Stochastic is 31 (neutral).
HIVE PE vs Financial Services Sector
| Metric | HIVE | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 13x | — |
HIVE has no meaningful PE right now: it lost money over the past year.
JPM PE vs Financial Services Sector
| Metric | JPM | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 13x | 10% above |
| PE % | 76 | 63 | 13 pts above |
JPM is trading at 14x earnings, a 10% premium to the Financial Services sector's median of 13x.
HIVE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.24 | 26% below |
| 20 week MA | $2.70 | 39% below |
| 50 week MA | $2.79 | 41% below |
| 100 week MA | $2.78 | 41% below |
| 200 week MA | $3.12 | 47% below |
HIVE is in a downtrend: it's below all five of its weekly moving averages, and 47% below its 200-week average.
JPM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $336.8 | 1.8% above |
| 20 week MA | $345.3 | 0.7% below |
| 50 week MA | $323.2 | 6.1% above |
| 100 week MA | $298.9 | 15% above |
| 200 week MA | $236.6 | 45% above |
JPM has the edge over HIVE on trend strength, trading above more of its moving averages.
HIVE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $0.40 | $8.30 | +1975% |
| 2021 | $8.30 | $15.3 | +84% |
| 2022 | $15.3 | $1.59 | -90% |
| 2023 | $1.59 | $4.53 | +185% |
| 2024 | $4.53 | $2.97 | -34% |
| 2025 | $2.97 | $2.72 | -8.4% |
| 2026 YTD | $2.72 | $1.65 | -39% |
HIVE's yearly returns have swung widely, from +1975% in 2020 to −90% in 2022. It's down 39% so far in 2026.
JPM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $139.1 | $124.5 | -11% |
| 2021 | $124.5 | $157.3 | +26% |
| 2022 | $157.3 | $131.3 | -17% |
| 2023 | $131.3 | $170.1 | +30% |
| 2024 | $170.1 | $241.2 | +42% |
| 2025 | $241.2 | $327.9 | +36% |
| 2026 YTD | $327.9 | $342.8 | +4.5% |
JPM has the edge over HIVE on returns for 2026, with the stronger performance.